ArticleMMWR. Morbidity and mortality weekly report2021
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Article in MMWR. Morbidity and mortality weekly report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.Human vaccines & immunotherapeutics · 2026Article
- Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.NPJ vaccines · 2025Review
- Body Mass Index and Hemoglobin A1c Correlate with Clinical Needs After COVID-19 Vaccination in the Veterans Affairs System.Journal of clinical medicine · 2025Article
- The role of mRNA vaccines in infectious diseases: a new era of immunization.Tropical diseases, travel medicine and vaccines · 2025Review
- IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19.Pediatric nephrology (Berlin, Germany) · 2025Review
- Sustained excess all-cause mortality post COVID-19 in 21 countries: an ecological investigation.International journal of epidemiology · 2025Article
- SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study.Infectious disease reports · 2024Article
- Article
- Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection.Signal transduction and targeted therapy · 2024Article
- Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.JAMA network open · 2024Article
- Article
- Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273.Open forum infectious diseases · 2024Article
- Article
- SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.The journal of allergy and clinical immunology. Global · 2023Article
- VA SHIELD: A Biorepository for Veterans and the Nation.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.Virology journal · 2023Article
- Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.PLoS medicine · 2023Observational
- Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada.Journal of the American Medical Directors Association · 2023Article
- Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study.The Lancet regional health. Western Pacific · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.